^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FOLH1 positive

    i
    Other names: FOLH1, FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA, Folate hydrolase 1, prostate-specific membrane antigen
    Entrez ID:
    2346
    Related biomarkers:
    Expression
    3d
    PSMA RNA aptamer A10-3.2 conjugated with indocyanine green for rapid intraoperative imaging and effective mild photothermal therapy of prostate cancer. (PubMed, Int J Biol Macromol)
    It also reduced SLC7A11 expression, suggesting a disruption of redox homeostasis in cancer cells. Taken together, this integrated strategy combining molecular targeting, real-time imaging, and localized mPTT, with optional gene regulation, offers a promising theranostic approach for precision management of PCa.
    Journal
    |
    SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    FOLH1 positive
    13d
    A single arm study of Androgen Receptor Pathway inhibition plus Adaptive-dosed [177Lu]Lu-PSMA-597 in metastatic hormone sensitive prostate cancer (OPTIMAL-e). (ACTRN12626000034336)
    P2, N=20, Not yet recruiting, St Vincent's Health Network
    New P2 trial
    |
    FOLH1 positive
    14d
    [ 18 F]PSMA Tracer and 131 I Avid Retroperitoneal Thyroid Tissue in a Patient with Synchronous Thyroid and Prostate Carcinomas: First Case Report and Literature Review. (PubMed, World J Nucl Med)
    High PSMA expression in differentiated thyroid cancer was associated with shorter progression-free survival and may be considered a marker of aggressiveness. Such tumors could be candidates for targeted PSMA-radioligand therapy (e.g., 177 lutetium), particularly in radioiodine-negative/refractory cases, which are difficult to treat.
    Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 positive
    1m
    Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=70 --> 29
    Enrollment closed • Enrollment change
    |
    FOLH1 positive
    1m
    A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=232, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FOLH1 positive
    1m
    PROQURE-1: EBRT + Lu-PSMA for N1M0 Prostate Cancer (clinicaltrials.gov)
    P1, N=14, Completed, The Netherlands Cancer Institute | N=24 --> 14 | Recruiting --> Completed
    Trial completion • Enrollment change
    |
    FOLH1 positive
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    1m
    Navigating the Scoring Systems and Interpretation Frameworks of Prostate-specific Membrane Antigen PET. (PubMed, Radiology)
    Nevertheless, such systems can be essential for optimizing prostate cancer management and facilitating communication among imaging professionals, clinicians, and patients. This article outlines these systems and discusses potential strengths and weaknesses.
    Review • Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 positive
    2ms
    PSMA PET in renal cell carcinoma: an update and future aspects. (PubMed, Semin Nucl Med)
    Early clinical experience with [¹⁷⁷Lu]Lu-PSMA radioligands and ongoing trials such as RENALUT and PRadR are exploring the feasibility of radioligand therapy targeting PSMA-positive ccRCC neovasculature. Although biological and kinetic barriers persist, PSMA-based imaging and therapy represent a feasible, rapidly translatable platform that bridges diagnosis and targeted treatment, marking a pivotal step towards personalised, imaging-guided management of advanced ccRCC.
    Review • Journal • IO biomarker
    |
    KDR (Kinase insert domain receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • EPAS1 (Endothelial PAS domain protein 1)
    |
    FOLH1 positive
    2ms
    PRESERVE-006: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC (clinicaltrials.gov)
    P1/2, N=148, Active, not recruiting, OncoC4, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FOLH1 positive
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • gotistobart (BNT316)
    3ms
    Diagnostic Performance of [18F]PSMA-1007 PET/CT on Proven PSMA-Positive Hepatocellular Carcinoma: A Prospective Clinical Study. (PubMed, J Nucl Med)
    High tracer accumulation in 70% of the participants suggests a possible use for PSMA-directed radiopharmaceutical therapy in an end-stage setting. However, PSMA expression was not prognostic for outcome, possibly because of the small sample size.
    Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 positive
    3ms
    CCTG PR21: 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer (clinicaltrials.gov)
    P2, N=200, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Jun 2026 --> Aug 2025
    Trial primary completion date
    |
    FOLH1 positive
    |
    docetaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    3ms
    PSMA-DC: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. (clinicaltrials.gov)
    P3, N=450, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Dec 2027 --> Apr 2028
    Trial primary completion date
    |
    FOLH1 positive
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)